文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

Landiolol用于脓毒性休克持续心动过速患者的心率控制:一项多中心随机临床试验(Landi-SEP)

Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP).
PubMed 文献 · Intensive Care Med · 2024-09-19
一句话结论在脓毒性休克持续心动过速患者中,Landiolol可在不增加血管加压药需求的情况下降低并维持心率,但28天死亡率与标准治疗无差异,结果不支持对未选择人群进行严格心率控制(<95次/分)。

这项多中心、开放标签、随机对照试验在7个欧洲国家20个中心于2018年至2022年纳入脓毒性休克伴持续心动过速的成人患者,比较Landiolol联合标准治疗(n=99)与单纯标准治疗(n=101)的疗效与安全性。主要复合终点为治疗开始后24小时内达到心率80-94次/分且不增加血管加压药需求并维持,Landiolol组达标比例显著高于对照组(39.8% [39/98] vs. 23.5% [23/98],组间差异16.5%,95%CI 3.4-28.8%,p=0.013)。关键次要终点28天死亡率和不良事件在两组间无统计学显著差异。作者结论认为,结合既往试验,结果不支持对未选择的脓毒性休克持续心动过速人群采取严格心率控制(<95次/分)策略,需进一步研究识别可能临床获益的患者表型。

要点

  • 脓毒性休克持续心动过速成人患者中,Landiolol组主要复合终点(24小时内HR 80-94次/分且不增加血管加压药需求并维持)达标率39.8%(39/98),对照组23.5%(23/98),组间差异16.5%(95%CI 3.4-28.8%,p=0.013)。
  • 28天死亡率和不良事件在Landiolol组与标准治疗组间无统计学显著差异。
  • 作者指出,结合既往试验,结果不支持对未选择的脓毒性休克持续心动过速人群采取严格心率控制(<95次/分)策略。
  • 作者认为需进一步研究识别能从心率控制中临床获益的脓毒性休克患者表型。

适用人群与场景

  • 成人脓毒性休克伴持续心动过速患者,随机分组接受Landiolol联合标准治疗(n=99)或单纯标准治疗(n=101)。

诊断标准与关键阈值

  • 主要复合终点:治疗开始后24小时内达到心率80-94次/分且不增加血管加压药需求并维持。

处置流程与药物剂量

  • Landiolol为可滴定、高选择性、超短效β1受体阻滞剂,与标准治疗联合使用,目标心率范围80-94次/分,治疗开始后24小时内评估。

研究设计与关键结果

  • 多中心、开放标签、随机对照试验,2018年至2022年在7个欧洲国家20个中心纳入196例脓毒性休克患者,Landiolol组98例、标准治疗组98例完成分析。
  • 主要复合终点达标率Landiolol组39.8%(39/98) vs. 对照组23.5%(23/98),组间差异16.5%(95%CI 3.4-28.8%,p=0.013)。
  • 关键次要终点28天死亡率和不良事件在两组间无统计学显著差异。

证据类型、等级与局限

  • 随机、开放标签、对照试验;原文未报告证据等级。
  • 局限:作者指出需进一步研究识别能从心率控制中临床获益的脓毒性休克患者表型。

对床旁实践的改变

  • 作者结论认为,结合既往试验,结果不支持对未选择的脓毒性休克持续心动过速人群采取严格心率控制(<95次/分)策略。
  • Landiolol可在不增加血管加压药需求的情况下降低并维持心率,但28天死亡率和不良事件与标准治疗无差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Excessive tachycardia in resuscitated septic shock patients can impair hemodynamics and worsen patient outcome. We investigated whether heart rate (HR) control can be achieved without increased vasopressor requirements using the titratable highly selective, ultra-short-acting β1-blocker landiolol.

METHODS: This randomized, open-label, controlled trial was conducted at 20 sites in 7 European countries from 2018 to 2022 and investigated the efficacy and safety of landiolol in adult patients with septic shock and persistent tachycardia. Patients were randomly assigned to receive either landiolol along with standard treatment (n = 99) or standard treatment alone (n = 101). The combined primary endpoint was HR response (i.e., HR within the range of 80-94 beats per minute) and its maintenance without increasing vasopressor requirements during the first 24 h after treatment start. Key secondary endpoints were 28-day mortality and adverse events.

RESULTS: Out of 196 included septic shock patients, 98 received standard treatment combined with landiolol and 98 standard treatment alone. A significantly larger proportion of patients met the combined primary endpoint in the landiolol group than in the control group (39.8% [39/98] vs. 23.5% [23/98]), with a between-group difference of 16.5% (95% confidence interval [CI]: 3.4-28.8%; p = 0.013). There were no statistically significant differences between study groups in tested secondary outcomes and adverse events.

CONCLUSION: The ultra-short-acting beta-blocker landiolol was effective in reducing and maintaining HR without increasing vasopressor requirements after 24 h in patients with septic shock and persistent tachycardia. There were no differences in adverse events and clinical outcomes such as 28-day mortality vs. standard of care. The results of this study, in the context of previous trials, do not support a treatment strategy of stringent HR reduction (< 95 bpm) in an unselected septic shock population with persistent tachycardia. Further investigations are needed to identify septic shock patient phenotypes that benefit clinically from HR control.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Rehberg S, Frank S, Černý V, et al. Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP). Intensive Care Med. 2024. PMID: 39297945. doi:10.1007/s00134-024-07587-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。